Advertisement

Clinical Drug Investigation

, Volume 11, Supplement 2, pp 15–24 | Cite as

Clinical Efficacy of Pefloxacin in Complicated Urinary Tract Infections, Uncomplicated Gonococcal Urethritis, Prostatitis and Epididymitis

An Overview
  • Kurt G. Naber
Article
  • 6 Downloads

Summary

This paper reviews the antibacterial in vitro activity of pefloxacin against uropathogens associated with complicated and/or hospital-acquired urinary tract infections (UTIs) and presents data from published studies investigating the therapy of complicated UTIs (including acute pyelonephritis), uncomplicated gonococcal urethritis, bacterial prostatitis, and epididymitis. Results from the published literature have demonstrated that pefloxacin is a useful treatment alternative in complicated UTIs with or without pyelonephritis, as single dose therapy in uncomplicated gonococcal urethritis in men, and in acute exacerbation of bacterial prostatitis and acute epididymitis. In a number of controlled studies investigating the efficacy and safety of pefloxacin in complicated UTI/pyelonephritis, results were similar to those with the comparator agents (ofloxacin, gentamicin or cefotaxime), although patient population sizes were not large enough to allow for the testing of equivalence according to accepted statistical methods. According to 2 dose-finding studies, it would appear desirable to investigate a once-daily regimen more closely, using either pefloxacin 800 or 400mg, considering the advantages of improved patient compliance.

Keywords

Cefotaxime Ofloxacin Prostatitis Drug Invest Bacteriuria 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schaeffer AJ. Diagnostics and categories of patients. Infection 1992; 20Suppl. 3: S138–42PubMedCrossRefGoogle Scholar
  2. 2.
    Naber KG, Bauernfeind A, Dietlein G, et al. Urinary pathogens and bacterial sensitivity in hospitalized urological patients based upon clinical aspects. Scand J Urol Nephrol 1987; Suppl.104: 47–57Google Scholar
  3. 3.
    Naber KG, Witte W, Bauernfeind A, et al. Resistenzentwicklung gegenüber Fluorochinolonen. Untersuchungen mit Erregern von Patienten mit komplizierten Harnwegsinfektionen. Chemotherapie Journal 1993; 2: 106–11Google Scholar
  4. 4.
    Piccolomini R, Cellini L, Allocati N, et al. In vitro activity of pefloxacin compared with five other quinolones on nalidixic acid-resistant Proteae species. Chemioterapia 1988; 7: 287–91PubMedGoogle Scholar
  5. 5.
    Peeling RW, Ronald AR. Use of quinolones in sexually transmitted diseases. In: Hooper DC, Wolfson JS, editors. Quinolone antimicrobial agents, 2nd ed. American Society for Microbiology, Washington DC, USA: 1993; 299–327Google Scholar
  6. 6.
    Hofbauer H, Kinzig M, Kresken M, et al. Urine bactericidal titers of norfloxacin and pefloxacin in volunteers receiving a single oral dose of 800mg [poster no. A 61]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy [ICAAC]. 1994 Oct 4-7; Orlando, 1994Google Scholar
  7. 7.
    Sörgel F, Naber KG, Stephan U. Pharmakokinetik und Analytik von Gyrase-Hemmern. I. Pharmakokinetik von GyraseHemmern - ein Überblick. Fortschritte der antimikrobiellen und antineoplastischen. Chemotherapie 1987; FAC 6-10: 1907–61Google Scholar
  8. 8.
    Montay G, Tassel JP. Improved high-performance liquid chromatographic determination of pefloxacin and its metabolite norfloxacin in human plasma and urine. J Chromatogr 1985; 339: 214–8PubMedCrossRefGoogle Scholar
  9. 9.
    Costa P, Galtier M, Laurelli JM, et al. Epididymites aiguës et antibiotherapie: mesure de la diffusion epididymaire de la pefloxacine. (Acute epididymitis and antibiotherapy: measurement of the epididymal diffusion of pefloxacin.) J Urol (Paris) 1989; 95(1): 41–4Google Scholar
  10. 10.
    Costa P, Louis JF, Mottet N, et al. Acute epididymitis and pefloxacin in mono-antibiotic therapy. Eur J C1in Microbiol Infect Dis [special issue] 1991: 626Google Scholar
  11. 11.
    Boerema JBJ, Pauwels R, Scheepers J, et al. Efficacy and safety of pefloxacin in the treatment of patients with complicated urinary tract infections. J Antimicrob Chemother 1984; 17Suppl. B: 103–9Google Scholar
  12. 12.
    Wittenberger R, Bauernfeind A. Treatment of urinary tract infections with pefloxacin: efficacy, safety and pharmacokinetics [P-12-39]. 14th International Congress of Chemotherapy; Kyoto, 1985Google Scholar
  13. 13.
    Glupczynski Y, Byl B, Dediste A, et al. Clinical evaluation of pefloxacin in adult patients with complicated urinary tract infections [abstract 181].International Symposium on New Quinolones. 1986 Jul 17-19; Geneva, 1986Google Scholar
  14. 14.
    Tripi M, Falletta C, Barbera M, et al. La pefloxacina nel trattamento delle infezioni delle vie urinaire. Urologia 1986; 53: 517–20Google Scholar
  15. 15.
    Seddik M, Youcef Khodja S, Charif N, et al. Pefloxacin in the treatment of nosocomial urinary tract infections [abstract 163]. 2nd International Symposium on New Quinolones. 1988 Aug 25-27; Geneva, 1988Google Scholar
  16. 16.
    Chan PCK, Cheng IKP, Chan MK, et al. Clinical experience with pefloxacin in patients with urinary tract infections. Br J C1in Pract 1990; 44: 564–7Google Scholar
  17. 17.
    Oksa A, Dzúriková V, Gajdos M, et al. Pefloxacin v liecbe recidivujúcich infekcií mocových ciest. (Pefloxacine in the treatment of relapsing infections of the urinary tract). Cas Lék Cesk 1990; 129: 953–6PubMedGoogle Scholar
  18. 18.
    Auguet T, Saballs P, Mattar S, et al. Pefloxacino en el tratamiento de las pielonefritis agudas: estudio clínico de 30 casos. Reu Esp Quimioterap 1991; 4: 59–61Google Scholar
  19. 19.
    Nguyen TV, Daglish B, Matthews JA. The Pefloxacin in UTI Study Group. Pefloxacin in serious complicated urinary tract infections (UTI) - once-daily dosing versus twice daily dosing; a double-blind study [abstract]. 5th International Symposium on New Quinolones. 1994 Aug 25-27; Singapore, 1994: 231Google Scholar
  20. 20.
    Meurice J. An open randomized comparison of 2 different dosage regimens of pefloxacin in the treatment of complicated UTI in elderly [abstract 1401]. 15th International Congress of Chemotherapy. 1987 JuI19-24; Istanbul, 1987: 364Google Scholar
  21. 21.
    Naber KG. Use of quinolones in urinary tract infections and prostatitis. Rev Infect Dis 1989; 11Suppl. 5: S1321–37PubMedCrossRefGoogle Scholar
  22. 22.
    Dewilde LTP. Efficacy and safety of pefloxacin in the treatment of patients with complicated urinary tract infections or postoperative infections after urinary tract surgery [abstract 27]. 1st International Meeting on Pefloxacin. 1990 Mar 22-23; Lisbon, 1990Google Scholar
  23. 23.
    Magyar T, Graber H, Árr M, et al. Comparative trial of pefloxacin and ofloxacin in severe urinary tract infections. Rev Infect Dis 1989; 11Suppl. 5: S1351Google Scholar
  24. 24.
    Sugandi S. The efficacy and safety of pefloxacin versus gentamicin in the treatment of renal stone patients with infections caused by susceptible micro-organisms: a preliminary report. Proceedings of the 1st Asian Symposium on Pefloxacin. 1989 Apr 1; Jakarta, 1989: 49–53Google Scholar
  25. 25.
    Gorski J, Wehnert J, Lange D, et al. Klinische Studie von Pefloxacin (ABAKTAL®) in der Behandlung der akuten Pyelonephritis. Z Urol Nephrol 1990; 83: 55–60PubMedGoogle Scholar
  26. 26.
    Marini U, Terravova G. Pefloxacin versus cefotaxime in patients with complicated urinary tract infection. Eur J Clin Microbiol Infect Dis [special issue]: 1991: 625–6Google Scholar
  27. 27.
    Timmermann C, Hoepelman I, de Hond J, et al. Open, randomized comparison of pefloxacin and cefotaxime in the treatment of complicated urinary tract infections. Infection 1992; 20: 34–7CrossRefGoogle Scholar
  28. 28.
    Norrby SR. Design of clinical trials in patients with urinary tract infections. Infection 1992; 20Suppl. 3: S181–8PubMedCrossRefGoogle Scholar
  29. 29.
    Garrel JB, Thabaut A, Grossetete G, et al. Efficacy and safety of pefloxacin in male gonococcal urethritis [110 PS 4.6/4-10]. Proceedings of the 13th International Congress of Chemotherapy. 1983 Aug 28- Sep 2; Vienna, 1983Google Scholar
  30. 30.
    Ndoye I, Mboup S, Counillon E, et al. La gonococcie aiguë essai d’un traitement par la péfloxacine. Médecine d’Afrique Noire 1989; 36: 69–72Google Scholar
  31. 31.
    Ball M, Kanga JM, Meilo H, et al. Treatment of acute gonococcal urethritis in men with a single dose of 800mg pefloxacin. Br J Clin Pract 1990; 44: 140–1PubMedGoogle Scholar
  32. 32.
    Tio TT, Sindhunata IR, Wagenvoort JHT, et al. Pefloxacin compared with cefotaxime for treating men with uncomplicated gonococcal urethritis. J Antimicrob Chemother 1990; 26uppl. B: 141–6PubMedGoogle Scholar
  33. 33.
    Cheong LL, Chan RKW, Nadarajak M. Pefloxacin and ciprofloxacin in the treatment of uncomplicated gonococcal urethritis in males. Genitourin Med 1992; 68: 260–2PubMedGoogle Scholar
  34. 34.
    Pean Y, Bouffault P, Franceschini PH. Pefloxacin treatment of acute female gonococcia [abstract 310]. 4th Mediterranean Congress of Chemotherapy. 1984 Oct 19-25; Rhodes, 1984Google Scholar
  35. 35.
    Rhône Poulenc. Peflacin® pefloxacin: product monograph. Manchester; Adis Press International: 1988Google Scholar
  36. 36.
    Naber KG. Role of quinolones in treatment of chronic bacterial prostatitis. In: Hooper DC, Wolfson JS, editors. Quinolone antimicrobial agents, 2nd ed.; Washington DC: American Society for Microbiology; 1993: 285–97Google Scholar
  37. 37.
    Guibert J, Boutelier R, Guyot A. A clinical trial ofpefloxacin in prostatitis. J Antimicrob Chemother 1990; 26Suppl. B: 161–6PubMedGoogle Scholar
  38. 38.
    Meares EM, Stamey TA. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol 1968; 5: 492–518PubMedGoogle Scholar
  39. 39.
    Weidner W, Schiefer HG, Krauss H, et al. Chronic prostatitis: a thorough search for etiologically involved microorganisms in 1461 patients. Infection 1991; 191Suppl. 3: S119–25CrossRefGoogle Scholar
  40. 40.
    Hanus PM, Danzinger LH. Treatment of chronic bacterial prostatitis. Clin Pharm 1984; 3: 49–55PubMedGoogle Scholar
  41. 41.
    Guibert J, Acar JF. Ofloxacin (RU 43280) evaluation c1inique dans les infections urinaires et prostatiques. Pathol Biol (Paris) 1986; 34: 494–7Google Scholar
  42. 42.
    Pust RA, Ackenheil-Koppe HR, Gilbert P, et al. Clinical efficacy of ofloxacin (Tarivid®) in patients with chronic bacterial prostatitis: preliminary results. J Chemother 1989; 1Suppl. 4: 869–71PubMedGoogle Scholar
  43. 43.
    Schaeffer A, Darras FS. The efficacy of norfloxacin in the treatment of chronic bacterial prostatitis refractory to trimethoprim-sulfamethoxazole and/or carbenicillin. J Urol 1990; 144: 690–3PubMedGoogle Scholar
  44. 44.
    Weidner W, Schiefer HG, Brlihler E. Refractory chronic bacterial prostatitis: a re-evaluation of ciprofloxacin treatment after a median follow up of 30 months. J Urol 1991; 146: 350–2PubMedGoogle Scholar
  45. 45.
    Pfau A. Prostatitis: a continuing enigma. Urol Clin North Am 1986; 13: 695PubMedGoogle Scholar
  46. 46.
    Naber KG, Giamarellou H. Proposed study design in prostatitis. Infection 1994; 22Suppl. 1: 59–60CrossRefGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Kurt G. Naber
    • 1
    • 2
  1. 1.Urologic Clinic, Elisabeth HospitalStraubingGermany
  2. 2.Teaching Hospital of the Medical School of Technical University of MunichGermany

Personalised recommendations